{
    "response": "**Overall Treatment Decision:** Yes\u2014initiate\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous thiamine 500 mg TID for 2\u20133 days then taper\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Ophthalmoplegia and ataxia could represent Wernicke encephalopathy High benefit and minimal risk Should precede any glucose administration\n\n*   **Treatment:** Eye protection (lubricating drops/ointment, eyelid taping at night)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Severe bilateral ptosis and ophthalmoplegia risk exposure keratopathy\n\n*   **Treatment:** Physiotherapy and gait/balance training; occupational therapy\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Ataxia and spasticity causing functional impairment Reduces falls and deconditioning\n\n*   **Treatment:** Low molecular weight heparin for VTE prophylaxis\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Reduced mobility with bilateral pyramidal signs increases VTE risk\n\n*   **Treatment:** Intravenous immunoglobulin 2 g/kg over 2\u20135 days\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Consider if MRI/CSF/serology support Bickerstaff spectrum or if neurological deficits progress Balances potential benefit with resource use and adverse effects\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Use for inflammatory/demyelinating brainstem disease after infection excluded Await MRI/CSF to guide therapy\n\n*   **Treatment:** Empiric ampicillin plus gentamicin\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve for clinical or CSF evidence of Listeria rhombencephalitis Current afebrile, normal inflammatory markers\n\n*   **Treatment:** Baclofen or tizanidine for spasticity\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Introduce after acute diagnostic phase Titrate to symptom control while monitoring sedation\n\n*   **Treatment:** Treat reversible neuropathy causes (e.g., vitamin B12 replacement, glycaemic optimisation)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Initiate once laboratory confirmation available Targets suspected length-dependent neuropathy\n\n\ntreatments = [{\"treatment\": \"Intravenous thiamine 500 mg TID for 2\\u20133 days then taper\", \"timing\": \"Start Now\", \"reasons\": [\"Ophthalmoplegia and ataxia could represent Wernicke encephalopathy\", \"High benefit and minimal risk\", \"Should precede any glucose administration\"]}, {\"treatment\": \"Eye protection (lubricating drops/ointment, eyelid taping at night)\", \"timing\": \"Start Now\", \"reasons\": [\"Severe bilateral ptosis and ophthalmoplegia risk exposure keratopathy\"]}, {\"treatment\": \"Physiotherapy and gait/balance training; occupational therapy\", \"timing\": \"Start Now\", \"reasons\": [\"Ataxia and spasticity causing functional impairment\", \"Reduces falls and deconditioning\"]}, {\"treatment\": \"Low molecular weight heparin for VTE prophylaxis\", \"timing\": \"Start Now\", \"reasons\": [\"Reduced mobility with bilateral pyramidal signs increases VTE risk\"]}, {\"treatment\": \"Intravenous immunoglobulin 2 g/kg over 2\\u20135 days\", \"timing\": \"Delay\", \"reasons\": [\"Consider if MRI/CSF/serology support Bickerstaff spectrum or if neurological deficits progress\", \"Balances potential benefit with resource use and adverse effects\"]}, {\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Delay\", \"reasons\": [\"Use for inflammatory/demyelinating brainstem disease after infection excluded\", \"Await MRI/CSF to guide therapy\"]}, {\"treatment\": \"Empiric ampicillin plus gentamicin\", \"timing\": \"Delay\", \"reasons\": [\"Reserve for clinical or CSF evidence of Listeria rhombencephalitis\", \"Current afebrile, normal inflammatory markers\"]}, {\"treatment\": \"Baclofen or tizanidine for spasticity\", \"timing\": \"Delay\", \"reasons\": [\"Introduce after acute diagnostic phase\", \"Titrate to symptom control while monitoring sedation\"]}, {\"treatment\": \"Treat reversible neuropathy causes (e.g., vitamin B12 replacement, glycaemic optimisation)\", \"timing\": \"Delay\", \"reasons\": [\"Initiate once laboratory confirmation available\", \"Targets suspected length-dependent neuropathy\"]}]"
}